%0 Journal Article %1 Schuetz2017K4DD %A Schuetz, Doris A. %A de Witte, Wilhelmus Egbertus Arnout %A Wong, Yin Cheong %A Knasmueller, Bernhard %A Richter, Lars %A Kokh, Daria B. %A Sadiq, S. Kashif %A Bosma, Reggie %A Nederpelt, Indira %A Heitman, Laura H. %A Segala, Elena %A Amaral, Marta %A Guo, Dong %A Andres, Dorothee %A Georgi, Victoria %A Stoddart, Leigh A. %A Hill, Steve %A Cooke, Robert M. %A Graaf, Chris De %A Leurs, Rob %A Frech, Matthias %A Wade, Rebecca C. %A de Lange, Elizabeth Cunera Maria %A IJzerman, Adriaan P. %A Müller-Fahrnow, Anke %A Ecker, Gerhard F. %D 2017 %J Drug Discovery Today %K drug-design drug-kinetics k4dd kinetics kinetics-drug-design %N 6 %P 896 - 911 %R http://dx.doi.org/10.1016/j.drudis.2017.02.002 %T Kinetics for Drug Discovery: an industry-driven effort to target drug residence time %U http://www.sciencedirect.com/science/article/pii/S1359644617300958 %V 22 %X A considerable number of approved drugs show non-equilibrium binding characteristics, emphasizing the potential role of drug residence times for in vivo efficacy. Therefore, a detailed understanding of the kinetics of association and dissociation of a target–ligand complex might provide crucial insight into the molecular mechanism-of-action of a compound. This deeper understanding will help to improve decision making in drug discovery, thus leading to a better selection of interesting compounds to be profiled further. In this review, we highlight the contributions of the Kinetics for Drug Discovery (K4DD) Consortium, which targets major open questions related to binding kinetics in an industry-driven public–private partnership.

@article{Schuetz2017K4DD, abstract = {A considerable number of approved drugs show non-equilibrium binding characteristics, emphasizing the potential role of drug residence times for in vivo efficacy. Therefore, a detailed understanding of the kinetics of association and dissociation of a target–ligand complex might provide crucial insight into the molecular mechanism-of-action of a compound. This deeper understanding will help to improve decision making in drug discovery, thus leading to a better selection of interesting compounds to be profiled further. In this review, we highlight the contributions of the Kinetics for Drug Discovery (K4DD) Consortium, which targets major open questions related to binding kinetics in an industry-driven public–private partnership.}, added-at = {2017-07-25T18:58:11.000+0200}, author = {Schuetz, Doris A. and de Witte, Wilhelmus Egbertus Arnout and Wong, Yin Cheong and Knasmueller, Bernhard and Richter, Lars and Kokh, Daria B. and Sadiq, S. Kashif and Bosma, Reggie and Nederpelt, Indira and Heitman, Laura H. and Segala, Elena and Amaral, Marta and Guo, Dong and Andres, Dorothee and Georgi, Victoria and Stoddart, Leigh A. and Hill, Steve and Cooke, Robert M. and Graaf, Chris De and Leurs, Rob and Frech, Matthias and Wade, Rebecca C. and de Lange, Elizabeth Cunera Maria and IJzerman, Adriaan P. and Müller-Fahrnow, Anke and Ecker, Gerhard F.}, biburl = {https://www.bibsonomy.org/bibtex/2812f17aea500d7b4f395940f0ac81961/salotz}, doi = {http://dx.doi.org/10.1016/j.drudis.2017.02.002}, interhash = {f58d5727a5303725b362768746bacd60}, intrahash = {812f17aea500d7b4f395940f0ac81961}, issn = {1359-6446}, journal = {Drug Discovery Today}, keywords = {drug-design drug-kinetics k4dd kinetics kinetics-drug-design}, number = 6, pages = {896 - 911}, timestamp = {2017-07-25T18:58:11.000+0200}, title = {Kinetics for Drug Discovery: an industry-driven effort to target drug residence time}, url = {http://www.sciencedirect.com/science/article/pii/S1359644617300958}, volume = 22, year = 2017 }